Equities Analysts Offer Predictions for CymaBay Therapeutics Inc’s Q2 2019 Earnings (NASDAQ:CBAY)

Equities Analysts Offer Predictions for CymaBay Therapeutics Inc’s Q2 2019 Earnings (NASDAQ:CBAY)

CymaBay Therapeutics Inc (NASDAQ:CBAY) – Equities research analysts at SunTrust Banks reduced their Q2 2019 earnings per share (EPS) estimates for shares of CymaBay Therapeutics in a report issued on Wednesday, May 15th, Zacks Investment Research reports. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will earn ($0.36) per share for the quarter, down from their previous forecast of ($0.34). SunTrust Banks also issued estimates for CymaBay Therapeutics’ Q3 2019 earnings at ($0.38) EPS, Q4 2019 earnings at ($0.39) EPS, FY2019 earnings at ($1.50) EPS, FY2020 earnings at ($1.63) EPS, FY2021 earnings at ($1.86) EPS, FY2022 earnings at ($1.61) EPS and FY2023 earnings at $0.63 EPS.

Several other equities research analysts have also recently commented on CBAY. Oppenheimer set a $18.00 target price on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Friday, February 15th. Piper Jaffray Companies set a $30.00 target price on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 20th. Roth Capital reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 19th. Leerink Swann began coverage on CymaBay Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $22.00 target price for the company. Finally, BidaskClub raised CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.44.

Shares of CBAY stock traded up $0.58 on Monday, hitting $6.75. The company had a trading volume of 3,282,237 shares, compared to its average volume of 986,123. The stock has a market cap of $415.60 million, a price-to-earnings ratio of -5.36 and a beta of 1.73. The company has a current ratio of 18.66, a quick ratio of 18.66 and a debt-to-equity ratio of 0.01. CymaBay Therapeutics has a twelve month low of $4.82 and a twelve month high of $15.00.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03).

A number of institutional investors have recently made changes to their positions in CBAY. Wellington Management Group LLP acquired a new stake in CymaBay Therapeutics in the first quarter valued at approximately $24,090,000. Perceptive Advisors LLC grew its stake in CymaBay Therapeutics by 71.1% in the first quarter. Perceptive Advisors LLC now owns 4,212,821 shares of the biopharmaceutical company’s stock valued at $55,946,000 after acquiring an additional 1,750,000 shares during the period. Great Point Partners LLC acquired a new stake in CymaBay Therapeutics in the fourth quarter valued at approximately $11,164,000. Vivo Capital LLC grew its stake in CymaBay Therapeutics by 126.9% in the first quarter. Vivo Capital LLC now owns 2,056,000 shares of the biopharmaceutical company’s stock valued at $27,304,000 after acquiring an additional 1,150,000 shares during the period. Finally, BlackRock Inc. grew its stake in CymaBay Therapeutics by 16.3% in the fourth quarter. BlackRock Inc. now owns 5,161,581 shares of the biopharmaceutical company’s stock valued at $40,622,000 after acquiring an additional 722,753 shares during the period. 99.53% of the stock is owned by hedge funds and other institutional investors.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Share:
Scroll Up